APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nuclear Medicine

Nuclear Medicine，or Radiopharmaceuticals， are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Nuclear Medicine，or Radiopharmaceuticals， are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.

Selected research

Market Analysis & Forecast

Global Nuclear Medicine Market Analysis and Forecast 2026-2032

1 January 2026190 pages

Choose your research edition.

Industry ResearchNuclear Medicine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Nuclear Medicine Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Nuclear Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nuclear Medicine Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Nuclear Medicine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Nuclear Medicine，or Radiopharmaceuticals， are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.

North America is the largest consumption area, with a consumption market share nearly 50%. Following North America, Europe is the second place consumption region with the consumption market share of about 25%.

Global Nuclear Medicine key manufacturers include GE Healthcare, Bracco Imaging, etc. The global top 2 manufacturers account for over 30 percent of total share.

Read the full market overview

The classification of Nuclear Medicine includes Tc-99, I-123/131, In-111, Xe-133, Th-201 and Ga-67, and the proportion of Tc-99 is about 50%.

Nuclear Medicine is widely used in Diagnostic, Therapeutic. The most proportion of Nuclear Medicine is Diagnostic, and the market share is over 60%.

Report Includes

This report presents an overview of global market for Nuclear Medicine, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Nuclear Medicine, also provides the revenue of main regions and countries. Of the upcoming market potential for Nuclear Medicine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Nuclear Medicine revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Nuclear Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Nuclear Medicine revenue, projected growth trends, production technology, application and end-user industry.

Nuclear Medicine Segment by Company

GE Healthcare

Bracco Imaging

Mallinckrodt

Lantheus Medical Imaging

Bayer

Triad Isotopes

Nordion

Jubilant Pharma

Eli Lilly

SIEMENS

China Isotope & Radiation

Dongcheng

Nuclear Medicine Segment by Type

Tc-99

I-123/131

In-111

Xe-133

Th-201

Ga-67

Others

Nuclear Medicine Segment by Application

Diagnostic

Therapeutic

Nuclear Medicine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nuclear Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Nuclear Medicine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Nuclear Medicine company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nuclear Medicine revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Nuclear Medicine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Tc-99 Major Player Table 3. I-123/131 Major Player Table 4. In-111 Major Player Table 5. Xe-133 Major Player Table 6. Th-201 Major Player Table 7. Ga-67 Major Player Table 8. Others Major Player Table 9. Global Nuclear Medicine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 10. Diagnostic Major Player Table 11. Therapeutic Major Player Table 12. Nuclear Medicine Industry Trends Table 13. Nuclear Medicine Industry Drivers Table 14. Nuclear Medicine Industry Opportunities and Challenges Table 15. Nuclear Medicine Industry Restraints Table 16. Global Nuclear Medicine Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Nuclear Medicine Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Nuclear Medicine Market Share by Region (2021-2026) Table 19. Global Nuclear Medicine Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Nuclear Medicine Market Share by Region (2027-2032) Table 21. Global Nuclear Medicine Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Nuclear Medicine Revenue Market Share by Players (2021-2026) Table 23. Global Nuclear Medicine Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Nuclear Medicine Key Players Headquarters & Area Served Table 25. Global Nuclear Medicine Players, Product Type & Application Table 26. Global Nuclear Medicine Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Nuclear Medicine by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Nuclear Medicine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Nuclear Medicine Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Nuclear Medicine Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Nuclear Medicine Revenue Market Share by Type (2021-2026) Table 33. Global Nuclear Medicine Revenue Market Share by Type (2027-2032) Table 34. Global Nuclear Medicine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Nuclear Medicine Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Nuclear Medicine Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Nuclear Medicine Revenue Market Share by Application (2021-2026) Table 38. Global Nuclear Medicine Revenue Market Share by Application (2027-2032) Table 39. GE Healthcare Company Information Table 40. GE Healthcare Business Overview Table 41. GE Healthcare Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. GE Healthcare Nuclear Medicine Product Portfolio Table 43. GE Healthcare Recent Development Table 44. Bracco Imaging Company Information Table 45. Bracco Imaging Business Overview Table 46. Bracco Imaging Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Bracco Imaging Nuclear Medicine Product Portfolio Table 48. Bracco Imaging Recent Development Table 49. Mallinckrodt Company Information Table 50. Mallinckrodt Business Overview Table 51. Mallinckrodt Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Mallinckrodt Nuclear Medicine Product Portfolio Table 53. Mallinckrodt Recent Development Table 54. Lantheus Medical Imaging Company Information Table 55. Lantheus Medical Imaging Business Overview Table 56. Lantheus Medical Imaging Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Lantheus Medical Imaging Nuclear Medicine Product Portfolio Table 58. Lantheus Medical Imaging Recent Development Table 59. Bayer Company Information Table 60. Bayer Business Overview Table 61. Bayer Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Bayer Nuclear Medicine Product Portfolio Table 63. Bayer Recent Development Table 64. Triad Isotopes Company Information Table 65. Triad Isotopes Business Overview Table 66. Triad Isotopes Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Triad Isotopes Nuclear Medicine Product Portfolio Table 68. Triad Isotopes Recent Development Table 69. Nordion Company Information Table 70. Nordion Business Overview Table 71. Nordion Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Nordion Nuclear Medicine Product Portfolio Table 73. Nordion Recent Development Table 74. Jubilant Pharma Company Information Table 75. Jubilant Pharma Business Overview Table 76. Jubilant Pharma Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Jubilant Pharma Nuclear Medicine Product Portfolio Table 78. Jubilant Pharma Recent Development Table 79. Eli Lilly Company Information Table 80. Eli Lilly Business Overview Table 81. Eli Lilly Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Eli Lilly Nuclear Medicine Product Portfolio Table 83. Eli Lilly Recent Development Table 84. SIEMENS Company Information Table 85. SIEMENS Business Overview Table 86. SIEMENS Nuclear Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. SIEMENS Nuclear Medicine Product Portfolio Table 88. SIEMENS Recent Development Table 89. China Isotope & Radiation Company Information Table 90. China Isotope & Radiation Business Overview Table 91. China Isotope & Radiation Nuclear Medicine Sales (M Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 92. China Isotope & Radiation Nuclear Medicine Product Portfolio Table 93. China Isotope & Radiation Recent Development Table 94. Dongcheng Company Information Table 95. Dongcheng Business Overview Table 96. Dongcheng Nuclear Medicine Sales (M Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 97. Dongcheng Nuclear Medicine Product Portfolio Table 98. Dongcheng Recent Development Table 99. North America Nuclear Medicine Revenue by Type (2021-2026) & (US$ Million) Table 100. North America Nuclear Medicine Revenue by Type (2027-2032) & (US$ Million) Table 101. North America Nuclear Medicine Revenue by Application (2021-2026) & (US$ Million) Table 102. North America Nuclear Medicine Revenue by Application (2027-2032) & (US$ Million) Table 103. North America Nuclear Medicine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. North America Nuclear Medicine Revenue by Country (2021-2026) & (US$ Million) Table 105. North America Nuclear Medicine Revenue by Country (US$ Million) & (2027-2032) Table 106. Europe Nuclear Medicine Revenue by Type (2021-2026) & (US$ Million) Table 107. Europe Nuclear Medicine Revenue by Type (2027-2032) & (US$ Million) Table 108. Europe Nuclear Medicine Revenue by Application (2021-2026) & (US$ Million) Table 109. Europe Nuclear Medicine Revenue by Application (2027-2032) & (US$ Million) Table 110. Europe Nuclear Medicine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 111. Europe Nuclear Medicine Revenue by Country (2021-2026) & (US$ Million) Table 112. Europe Nuclear Medicine Revenue by Country (US$ Million) & (2027-2032) Table 113. China Nuclear Medicine Revenue by Type (2021-2026) & (US$ Million) Table 114. China Nuclear Medicine Revenue by Type (2027-2032) & (US$ Million) Table 115. China Nuclear Medicine Revenue by Application (2021-2026) & (US$ Million) Table 116. China Nuclear Medicine Revenue by Application (2027-2032) & (US$ Million) Table 117. Asia Nuclear Medicine Revenue by Type (2021-2026) & (US$ Million) Table 118. Asia Nuclear Medicine Revenue by Type (2027-2032) & (US$ Million) Table 119. Asia Nuclear Medicine Revenue by Application (2021-2026) & (US$ Million) Table 120. Asia Nuclear Medicine Revenue by Application (2027-2032) & (US$ Million) Table 121. Asia Nuclear Medicine Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 122. Asia Nuclear Medicine Revenue by Region (US$ Million) & (2021-2026) Table 123. Asia Nuclear Medicine Revenue by Region (US$ Million) & (2027-2032) Table 124. SAMEA Nuclear Medicine Revenue by Type (2021-2026) & (US$ Million) Table 125. SAMEA Nuclear Medicine Revenue by Type (2027-2032) & (US$ Million) Table 126. SAMEA Nuclear Medicine Revenue by Application (2021-2026) & (US$ Million) Table 127. SAMEA Nuclear Medicine Revenue by Application (2027-2032) & (US$ Million) Table 128. SAMEA Nuclear Medicine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 129. SAMEA Nuclear Medicine Revenue by Country (2021-2026) & (US$ Million) Table 130. SAMEA Nuclear Medicine Revenue by Country (US$ Million) & (2027-2032) Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Nuclear Medicine Image Figure 2. Global Nuclear Medicine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nuclear Medicine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Tc-99 Image Figure 5. I-123/131 Image Figure 6. In-111 Image Figure 7. Xe-133 Image Figure 8. Th-201 Image Figure 9. Ga-67 Image Figure 10. Others Image Figure 11. Global Nuclear Medicine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Nuclear Medicine Market Size Share 2021 VS 2025 VS 2032 Figure 13. Diagnostic Image Figure 14. Therapeutic Image Figure 15. Global Nuclear Medicine Market Size (US$ Million) & (2021-2032) Figure 16. Global Nuclear Medicine Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Nuclear Medicine Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Nuclear Medicine Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Nuclear Medicine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Nuclear Medicine Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Nuclear Medicine Revenue Market Share by Type (2021-2032) Figure 23. Global Nuclear Medicine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Nuclear Medicine Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Nuclear Medicine Revenue Market Share by Application (2021-2032) Figure 26. North America Nuclear Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Nuclear Medicine Revenue Share by Type (2021-2032) Figure 28. North America Nuclear Medicine Revenue Share by Application (2021-2032) Figure 29. North America Nuclear Medicine Revenue Share by Country (2021-2032) Figure 30. United States Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Nuclear Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Nuclear Medicine Revenue Share by Type (2021-2032) Figure 35. Europe Nuclear Medicine Revenue Share by Application (2021-2032) Figure 36. Europe Nuclear Medicine Revenue Share by Country (2021-2032) Figure 37. Germany Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Nuclear Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Nuclear Medicine Revenue Share by Type (2021-2032) Figure 47. China Nuclear Medicine Revenue Share by Application (2021-2032) Figure 48. Asia Nuclear Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Nuclear Medicine Revenue Share by Type (2021-2032) Figure 50. Asia Nuclear Medicine Revenue Share by Application (2021-2032) Figure 51. Asia Nuclear Medicine Revenue Share by Region (2021-2032) Figure 52. Japan Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Nuclear Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Nuclear Medicine Revenue Share by Type (2021-2032) Figure 60. SAMEA Nuclear Medicine Revenue Share by Application (2021-2032) Figure 61. SAMEA Nuclear Medicine Revenue Share by Country (2021-2032) Figure 62. Brazil Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Nuclear Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Tc-99
  • I-123/131
  • In-111
  • Xe-133
  • Th-201
  • Ga-67
  • Others
Applications
  • Diagnostic
  • Therapeutic
Companies covered
  • GE Healthcare
  • Bracco Imaging
  • Mallinckrodt
  • Lantheus Medical Imaging
  • Bayer
  • Triad Isotopes
  • Nordion
  • Jubilant Pharma
  • Eli Lilly
  • SIEMENS
  • China Isotope & Radiation
  • Dongcheng

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Nuclear Medicine Market by Type
  3. 1.2.1 Global Nuclear Medicine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Tc-99
  5. 1.2.3 I-123/131
  6. 1.2.4 In-111
  7. 1.2.5 Xe-133
  8. 1.2.6 Th-201
  9. 1.2.7 Ga-67
  10. 1.2.8 Others
  11. 1.3 Nuclear Medicine Market by Application
  12. 1.3.1 Global Nuclear Medicine Market Size by Application, 2021 VS 2025 VS 2032
  13. 1.3.2 Diagnostic
  14. 1.3.3 Therapeutic
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Nuclear Medicine Market Dynamics
  1. 2.1 Nuclear Medicine Industry Trends
  2. 2.2 Nuclear Medicine Industry Drivers
  3. 2.3 Nuclear Medicine Industry Opportunities and Challenges
  4. 2.4 Nuclear Medicine Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Nuclear Medicine Market Perspective (2021-2032)
  2. 3.2 Global Nuclear Medicine Growth Trends by Region
  3. 3.2.1 Global Nuclear Medicine Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Nuclear Medicine Market Size by Region (2021-2026)
  5. 3.2.3 Global Nuclear Medicine Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Nuclear Medicine Revenue by Players
  2. 4.1.1 Global Nuclear Medicine Revenue by Players (2021-2026)
  3. 4.1.2 Global Nuclear Medicine Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Nuclear Medicine Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Nuclear Medicine Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Nuclear Medicine Key Players Headquarters & Area Served
  7. 4.4 Global Nuclear Medicine Players, Product Type & Application
  8. 4.5 Global Nuclear Medicine Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Nuclear Medicine Market CR5 and HHI
  11. 4.6.3 2025 Nuclear Medicine Tier 1, Tier 2, and Tier 3
5 Nuclear Medicine Market Size by Type
  1. 5.1 Global Nuclear Medicine Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Nuclear Medicine Revenue by Type (2021-2032)
  3. 5.3 Global Nuclear Medicine Revenue Market Share by Type (2021-2032)
6 Nuclear Medicine Market Size by Application
  1. 6.1 Global Nuclear Medicine Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Nuclear Medicine Revenue by Application (2021-2032)
  3. 6.3 Global Nuclear Medicine Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 GE Healthcare
  2. 7.1.1 GE Healthcare Company Information
  3. 7.1.2 GE Healthcare Business Overview
  4. 7.1.3 GE Healthcare Nuclear Medicine Revenue and Gross Margin (2021-2026)
  5. 7.1.4 GE Healthcare Nuclear Medicine Product Portfolio
  6. 7.1.5 GE Healthcare Recent Developments
  7. 7.2 Bracco Imaging
  8. 7.2.1 Bracco Imaging Company Information
  9. 7.2.2 Bracco Imaging Business Overview
  10. 7.2.3 Bracco Imaging Nuclear Medicine Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Bracco Imaging Nuclear Medicine Product Portfolio
  12. 7.2.5 Bracco Imaging Recent Developments
  13. 7.3 Mallinckrodt
  14. 7.3.1 Mallinckrodt Company Information
  15. 7.3.2 Mallinckrodt Business Overview
  16. 7.3.3 Mallinckrodt Nuclear Medicine Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Mallinckrodt Nuclear Medicine Product Portfolio
  18. 7.3.5 Mallinckrodt Recent Developments
  19. 7.4 Lantheus Medical Imaging
  20. 7.4.1 Lantheus Medical Imaging Company Information
  21. 7.4.2 Lantheus Medical Imaging Business Overview
  22. 7.4.3 Lantheus Medical Imaging Nuclear Medicine Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Lantheus Medical Imaging Nuclear Medicine Product Portfolio
  24. 7.4.5 Lantheus Medical Imaging Recent Developments
  25. 7.5 Bayer
  26. 7.5.1 Bayer Company Information
  27. 7.5.2 Bayer Business Overview
  28. 7.5.3 Bayer Nuclear Medicine Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Bayer Nuclear Medicine Product Portfolio
  30. 7.5.5 Bayer Recent Developments
  31. 7.6 Triad Isotopes
  32. 7.6.1 Triad Isotopes Company Information
  33. 7.6.2 Triad Isotopes Business Overview
  34. 7.6.3 Triad Isotopes Nuclear Medicine Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Triad Isotopes Nuclear Medicine Product Portfolio
  36. 7.6.5 Triad Isotopes Recent Developments
  37. 7.7 Nordion
  38. 7.7.1 Nordion Company Information
  39. 7.7.2 Nordion Business Overview
  40. 7.7.3 Nordion Nuclear Medicine Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Nordion Nuclear Medicine Product Portfolio
  42. 7.7.5 Nordion Recent Developments
  43. 7.8 Jubilant Pharma
  44. 7.8.1 Jubilant Pharma Company Information
  45. 7.8.2 Jubilant Pharma Business Overview
  46. 7.8.3 Jubilant Pharma Nuclear Medicine Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Jubilant Pharma Nuclear Medicine Product Portfolio
  48. 7.8.5 Jubilant Pharma Recent Developments
  49. 7.9 Eli Lilly
  50. 7.9.1 Eli Lilly Company Information
  51. 7.9.2 Eli Lilly Business Overview
  52. 7.9.3 Eli Lilly Nuclear Medicine Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Eli Lilly Nuclear Medicine Product Portfolio
  54. 7.9.5 Eli Lilly Recent Developments
  55. 7.10 SIEMENS
  56. 7.10.1 SIEMENS Company Information
  57. 7.10.2 SIEMENS Business Overview
  58. 7.10.3 SIEMENS Nuclear Medicine Revenue and Gross Margin (2021-2026)
  59. 7.10.4 SIEMENS Nuclear Medicine Product Portfolio
  60. 7.10.5 SIEMENS Recent Developments
  61. 7.11 China Isotope & Radiation
  62. 7.11.1 China Isotope & Radiation Company Information
  63. 7.11.2 China Isotope & Radiation Business Overview
  64. 7.11.3 China Isotope & Radiation Nuclear Medicine Revenue and Gross Margin (2021-2026)
  65. 7.11.4 China Isotope & Radiation Nuclear Medicine Product Portfolio
  66. 7.11.5 China Isotope & Radiation Recent Developments
  67. 7.12 Dongcheng
  68. 7.12.1 Dongcheng Company Information
  69. 7.12.2 Dongcheng Business Overview
  70. 7.12.3 Dongcheng Nuclear Medicine Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Dongcheng Nuclear Medicine Product Portfolio
  72. 7.12.5 Dongcheng Recent Developments
8 North America
  1. 8.1 North America Nuclear Medicine Revenue (2021-2032)
  2. 8.2 North America Nuclear Medicine Revenue by Type (2021-2032)
  3. 8.2.1 North America Nuclear Medicine Revenue by Type (2021-2026)
  4. 8.2.2 North America Nuclear Medicine Revenue by Type (2027-2032)
  5. 8.3 North America Nuclear Medicine Revenue Share by Type (2021-2032)
  6. 8.4 North America Nuclear Medicine Revenue by Application (2021-2032)
  7. 8.4.1 North America Nuclear Medicine Revenue by Application (2021-2026)
  8. 8.4.2 North America Nuclear Medicine Revenue by Application (2027-2032)
  9. 8.5 North America Nuclear Medicine Revenue Share by Application (2021-2032)
  10. 8.6 North America Nuclear Medicine Revenue by Country
  11. 8.6.1 North America Nuclear Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Nuclear Medicine Revenue by Country (2021-2026)
  13. 8.6.3 North America Nuclear Medicine Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Nuclear Medicine Revenue (2021-2032)
  2. 9.2 Europe Nuclear Medicine Revenue by Type (2021-2032)
  3. 9.2.1 Europe Nuclear Medicine Revenue by Type (2021-2026)
  4. 9.2.2 Europe Nuclear Medicine Revenue by Type (2027-2032)
  5. 9.3 Europe Nuclear Medicine Revenue Share by Type (2021-2032)
  6. 9.4 Europe Nuclear Medicine Revenue by Application (2021-2032)
  7. 9.4.1 Europe Nuclear Medicine Revenue by Application (2021-2026)
  8. 9.4.2 Europe Nuclear Medicine Revenue by Application (2027-2032)
  9. 9.5 Europe Nuclear Medicine Revenue Share by Application (2021-2032)
  10. 9.6 Europe Nuclear Medicine Revenue by Country
  11. 9.6.1 Europe Nuclear Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Nuclear Medicine Revenue by Country (2021-2026)
  13. 9.6.3 Europe Nuclear Medicine Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Nuclear Medicine Revenue (2021-2032)
  2. 10.2 China Nuclear Medicine Revenue by Type (2021-2032)
  3. 10.2.1 China Nuclear Medicine Revenue by Type (2021-2026)
  4. 10.2.2 China Nuclear Medicine Revenue by Type (2027-2032)
  5. 10.3 China Nuclear Medicine Revenue Share by Type (2021-2032)
  6. 10.4 China Nuclear Medicine Revenue by Application (2021-2032)
  7. 10.4.1 China Nuclear Medicine Revenue by Application (2021-2026)
  8. 10.4.2 China Nuclear Medicine Revenue by Application (2027-2032)
  9. 10.5 China Nuclear Medicine Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Nuclear Medicine Revenue (2021-2032)
  2. 11.2 Asia Nuclear Medicine Revenue by Type (2021-2032)
  3. 11.2.1 Asia Nuclear Medicine Revenue by Type (2021-2026)
  4. 11.2.2 Asia Nuclear Medicine Revenue by Type (2027-2032)
  5. 11.3 Asia Nuclear Medicine Revenue Share by Type (2021-2032)
  6. 11.4 Asia Nuclear Medicine Revenue by Application (2021-2032)
  7. 11.4.1 Asia Nuclear Medicine Revenue by Application (2021-2026)
  8. 11.4.2 Asia Nuclear Medicine Revenue by Application (2027-2032)
  9. 11.5 Asia Nuclear Medicine Revenue Share by Application (2021-2032)
  10. 11.6 Asia Nuclear Medicine Revenue by Country
  11. 11.6.1 Asia Nuclear Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Nuclear Medicine Revenue by Country (2021-2026)
  13. 11.6.3 Asia Nuclear Medicine Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Nuclear Medicine Revenue (2021-2032)
  2. 12.2 SAMEA Nuclear Medicine Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Nuclear Medicine Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Nuclear Medicine Revenue by Type (2027-2032)
  5. 12.3 SAMEA Nuclear Medicine Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Nuclear Medicine Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Nuclear Medicine Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Nuclear Medicine Revenue by Application (2027-2032)
  9. 12.5 SAMEA Nuclear Medicine Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Nuclear Medicine Revenue by Country
  11. 12.6.1 SAMEA Nuclear Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Nuclear Medicine Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Nuclear Medicine Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst